A relationship is considered to be modest if it is less than significant under the preceding definition. *Modest. Significant. Reviewer Disclosures Reviewer Employment Research Grant Other Research Support Speakers Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other Elliott M. Antman Brigham & Women s Hospital None None None None None None None Jeffrey L. Anderson Intermountain Medical Center None None None None None AstraZeneca* None Gary J. Balady Boston Medical Center None None None None None None None Eric R. Bates University of Michigan None None None None None AstraZeneca*; Daiichi Sankyo*; Eli Lilly*; Merck*; Sanofi Aventis* None Vera Bittner University of Alabama at Birmingham Clinical site PI for multicenter trials funded by: Roche/Genentech ; Gilead; GSK ; NIH/Abbott ; NIH/Yale None None None None Roche/Genentech*; Amarin*; Pfizer* None Ann F. Bolger University of California, San Francisco None None None None None None None Victor A. Ferrari University of Pennsylvania None None None None None Board of Trustees, Society for Cardiovascular Magnetic Resonance (no monetary value)*; Editorial Board, Journal of Cardiovascular Magnetic Resonance (no monetary value)* None Stephan Fihn Department of Veterans Affairs and University of Washington None None None None None None None Gregg Fonarow UCLA NHLBI ; AHRQ None None None None Novartis ; Medtronic* None Federico Gentile Centro Medico diagnostic, Naples-Italy None None None None None None None Larry B. Goldstein Duke University None None None None None None None Jonathan Halperin Mount Sinai Medical Center, New York, NY None None None None None Boehringer Ingelheim ; Astellas Pharma, US*; Bristol-Meyers Squibb*; Daiichi Sankyo*; Johnson & Johnson*; Pfizer, Inc*; Sanofi-Aventis* None (Continued) References 1. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. 